Related Experiment Video
Updated: Feb 26, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Living with the Effects of Cutaneous Toxicities Induced by Treatment
1Department of Nursing, Cyprus University of Technology, Limassol, Cyprus, Finland.
Abstract:
The introduction of targeted therapies in cancer treatment was accompanied with promising results including tumor control and patients survival benefits. However, these drugs just like their predecessors were associated with systemic side effects, including frequent and various cutaneous effects. Targeted therapies such as epidermal growth factor receptor, vascular endothelial growth factor receptor, kit, platelet-derived growth factor receptor, and BCR-ABL inhibitors as well as mammalian target of rapamycin inhibitors can induce cutaneous toxicities of varying severity. There are scarce studies on the actual impact of these toxicities on the patients' lives including the physical, social, and psychological aspects and overall quality of life. Patient's perspective in living with and beyond these toxicities remains largely uncharted but essential in optimizing care provided to those receiving treatment with targeted therapies.
Insights
Targeted cancer therapies cause skin side effects, impacting patients' physical, social, and psychological well-being. Understanding the patient experience is crucial for improving care and quality of life during treatment.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Targeted therapies offer significant cancer treatment benefits, including improved survival.
- These therapies frequently cause systemic side effects, notably various cutaneous toxicities.
- Specific drug classes implicated include EGFR, VEGF, KIT, PDGFR, BCR-ABL, and mTOR inhibitors.
Purpose of the Study:
- To investigate the impact of targeted therapy-induced cutaneous toxicities on patients' quality of life.
- To explore the physical, social, and psychological aspects of living with these side effects.
- To highlight the need for understanding the patient perspective in managing treatment toxicities.
Main Methods:
- Literature review on targeted therapies and their dermatological side effects.
- Analysis of existing studies on patient-reported outcomes and quality of life.
- Identification of research gaps concerning patient experiences with treatment toxicities.
Main Results:
- Cutaneous toxicities are common side effects of numerous targeted cancer therapies.
- Limited research exists on the comprehensive impact of these toxicities on patients' daily lives.
- The physical, social, and psychological burden on patients is not well-documented.
Conclusions:
- Targeted therapies, while effective, present significant dermatological challenges.
- Further research is essential to understand and address the patient experience of these toxicities.
- Incorporating patient perspectives is key to optimizing supportive care and improving quality of life for cancer patients.
More Related Videos
Related Concept Videos
Drug Toxicity: Allergic Reactions
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Drug Toxicity: Dose-Dependent Reactions
Burn Injuries
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

